SynthesisFrontiers in medicine2026
Anti-Müllerian hormone levels and live birth rate in polycystic ovary syndrome patients undergoing assisted reproductive technology: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anti-Müllerian hormone (AMH) is typically elevated in women with polycystic ovary syndrome (PCOS), but its relationship with assisted reproductive technology (ART) outcomes remains unclear. Objectives: This systematic review and meta-analysis aimed to evaluate the association between AMH levels and pregnancy outcomes in women with PCOS undergoing ART. Search methods: Observational studies published between January 2020 and May 2025 were identified from major databases. The search strategy incorporated controlled vocabulary and keywords related to "Polycystic Ovary Syndrome," "anti-Müllerian hormone," and ART outcomes. Eight studies were included. Main outcomes: Higher oocyte yields were observed across ascending AMH subgroups, with significant differences detected in all pairwise comparisons (low vs. high: MD = -3.91, 95% CI: -5.60 to -2.23; Z = 4.55, Conclusion: The distinct intermediate phenotype of the medium AMH group, exhibiting superior live birth outcomes compared to high AMH, yet inferior to low AMH, underscores the value of finer stratification beyond a simple binary classification. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier [CRD420251089070].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.